Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05650541 · ClinicalTrials.gov registry record · NA

Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

A NA study of Heart Failure, sponsored by Analog Device.

Recruiting
Registry status
NA
Development phase
1,200
Enrollment target
7
Study locations

NCT05650541: Recruiting NA study of Heart Failure, sponsored by Analog Device.

NCT05650541 is a NA study of Heart Failure that is actively recruiting participants, run by Analog Device. The registered enrollment target is 1,200 participants, below the 2,046-participant average among 397 other Heart Failure trials with a reported enrollment target (41% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05650541, a NA study of Heart Failure, is actively recruiting participants, sponsored by Analog Device.

RECRUITING
Registry status
NA
Development phase
1,200 participants
Enrollment target
7
Study locations

Study Summary

The primary purpose for this study is to support the hypothesis (pilot data) that the use of the Sensinel CPM system reduces the rate of HF-related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the primary objective, the study will compare the outcomes and costs for patients using the Sensinel CPM system against those who are not. This can either be done using institutions' averages, if available, or through a control group.

Primary Outcome

Admission rate for HF and HF related events in the study group vs. the institution's averages (and/or control group)

Conditions Studied

Interventions

  • DEVICE CardioPumlonary Management System

Study Locations (7)

Florida

  • Baptist Health South Florida - Miami
  • Orlando Health - Orlando

California

  • Desert Oasis Healthcare - Palm Springs

Massachusetts

  • Baystate Medical Center - Springfield

Nebraska

  • University of Nebraska Medical Center - Omaha

North Carolina

  • Cone Health - Greensboro

South Carolina

  • Prisma Health - Greenville

Trial Details

FieldValue
Enrollment Target 1,200 participants
Start Date 2023-09-22
Est. Completion 2026-06-01
Phase NA
Analog Device

5 total trials

What NCT05650541 shows while recruiting

NCT05650541 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, below the 2,046-participant average among 397 other Heart Failure trials with a reported enrollment target (41% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which CardioPumlonary Management System is the first listed.

NCT05650541 lists 7 locations in 6 states (Florida, California, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT05650541 about?

NCT05650541 is a clinical study titled "Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure". The primary purpose for this study is to support the hypothesis (pilot data) that the use of the Sensinel CPM system reduces the rate of HF-related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the prim...

What is the current status of trial NCT05650541?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,200 participants. The study started on 2023-09-22. Estimated completion is 2026-06-01.

What conditions does trial NCT05650541 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT05650541?

The interventions under investigation include: CardioPumlonary Management System (DEVICE).

Who is sponsoring clinical trial NCT05650541?

This trial is sponsored by Analog Device, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05650541 being conducted?

This trial has 7 study locations across California, Florida, Massachusetts, Nebraska, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05650541's enrollment target sits among peer trials

1,200 64th of 397 higher than 334 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001987 · 1,200 participants

    Genetic Studies of Insulin and Diabetes

  • NCT00477100 · 1,200 participants

    Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

  • NCT01209000 · 1,200 participants

    Nephrotic Syndrome Study Network

  • NCT01944332 · 1,200 participants · NA

    Gamete Treatment to Correct Fertilization Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05650541, the US trial registry maintained by the National Library of Medicine. NCT05650541 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.